Table 2 Management and outcome.
| Characteristic | Empirical antibiotic use | |||
|---|---|---|---|---|
| FQ (n = 79) | FQ, no underlying disease (n = 37) | Others (n = 218) | No (n = 251) | |
| Initial visit to ordering TB studies (days)* | 6 (0–173)†¶ | 6 (1–173) | 5 (0–163) | 5 (0–272) |
| AFS+ (n = 126) | 9 (1–173) | 4 (1–173) | 3 (0–78) | 3 (0–112) |
| AFS − (n = 422) | 6 (0–159) | 6 (1–61) | 5 (0–163) | 5 (0–272) |
| TB study to anti‐TB treatment (days)* | 25 (−3–231)†¶ | 31 (−3–73) | 7 (−35–143)‡ | 0 (−114–146) |
| AFS+ (n = 123) | 5 (1–21)† | 4 (2–9) | 2 (−16–98)‡ | −1 (−35–55) |
| AFS− (n = 363) | 31 (−3–231)†¶ | 33 (−3–73) | 16 (−35–143)‡ | 1 (−114–146) |
| Initial visit to anti‐TB treatment (days)* | 41 (6–233)†¶ | 38 (6–175) | 16 (0–198)‡ | 7 (0–286) |
| AFS+ (n = 123) | 15 (8–175)†¶ | 10 (8–175) | 6 (0–105)‡ | 3 (0–123) |
| AFS− (n = 363) | 42 (6–233)†¶ | 39 (6–96) | 27 (0–198)‡ | 13 (0–286) |
| Ordering TB study at initial visit | 53 (67.1%) | 26 (70.3%) | 163 (74.8%) | 179 (71.3%) |
| TB study to identification available (days)* | 63 (37–85) | 64 (55–82) | 62 (36–92) | 62 (35–121) |
| AFS+ (n = 126) | 63 (57–73) | 60 (57–62) | 63 (36–78) | 63 (50–77) |
| AFS− (n = 422) | 63 (37–85) | 64 (55–82) | 62 (54–92) | 62 (35–121) |
| Outcome | † | ‡ | ||
| Completed treatment | 41 (51.9%) | 23 (62.2%) | 133 (61.0%) | 198 (78.9%) |
| Ongoing treatment | 0 | 0 | 1 (0.5%) | 4 (1.6%) |
| Not treated | 2 (2.5%) | 2 (5.4%) | 5 (2.3%) | 1 (0.4%) |
| Lost to follow up | 13 (16.5%) | 7 (18.9%) | 34 (15.6%) | 33 (13.1%) |
| Mortality | 23 (29.1%) | 5 (13.5%) | 45 (20.6%) | 15 (6.0%) |
| Died of TB | 12 | 3 | 22 | 1 |
| Died with TB | 11 | 2 | 23 | 14 |
| Length of survival (days)* | 85.5 (18–448)† | 59 (26–448) | 55 (1–708)‡ | 249 (23–902) |
AFS, acid‐fast smear; TB, tuberculosis.
*Data presented as median (range).
†p<0.05 FQ group v no antibiotic group.
‡p<0.05 other antibiotic group v no antibiotic group.
¶p<0.05 FQ group v other antibiotic group.